Skip to content

Advertisement

  • Correction
  • Open Access

Correction to: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective

  • 1,
  • 2,
  • 2,
  • 3,
  • 4,
  • 1Email author,
  • 5,
  • 6,
  • 7 and
  • 8
Respiratory Research201920:18

https://doi.org/10.1186/s12931-019-0985-2

  • Received: 16 January 2019
  • Accepted: 16 January 2019
  • Published:

The original article was published in Respiratory Research 2018 19:224

Correction to: Respir Res

https://doi.org/10.1186/s12931-018-0916-7

Following publication of the original article [1], we have been notified of the below corrections to the 5th paragraph in the Discussion section.
  • Reference 24 needs to be amended to 25

  • The 12-week study needs to be corrected to 8-week study

Corrected text:

This study is the first to compare two LAMA/LABA dual therapies using direct head-to-head data from a randomized, 8-week study [25], which is the most reliable set of data to include within a cost-effectiveness model [25].

Notes

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Value Evidence and Outcomes, GSK, 980 Great West Road, Brentford, Middlesex, TW8 9GS, UK
(2)
ICON Health Economics, ICON plc, Abingdon, UK
(3)
Departamento de Evaluación de Medicamentos, GSK, Tres Cantos, Madrid, Spain
(4)
Global Respiratory Franchise, GSK, Brentford, Middlesex, UK
(5)
Hospital de Alta Resolución de Loja, Granada, Spain
(6)
Pneumology Department, Hospital Universitari Vall d’Hebron, Barcelona, Spain
(7)
Hospital Universitario La Paz-IdiPAZ, Madrid, Spain
(8)
ICON Health Economics, ICON, Toronto, ON, Canada

Reference

  1. Driessen, et al. Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective. Respir Res. 2018;19:224. https://doi.org/10.1186/s12931-018-0916-7.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2019

Advertisement